ArticlePloS one2022
Hemoadsorption in the critically ill-Final results of the International CytoSorb Registry.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02312024 (International Registry on the Use of the CytoSorb®-Adsorber in ICU Patients), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
International Registry on the Use of the CytoSorb®-Adsorber in ICU Patients
Who cites it
22 citing papers in PubMed.
- REmoval of cytokines during CArdiac surgery (RECCAS): a randomised controlled trial.Critical care (London, England) · 2024Trial
- The effect of hemoadsorption to patients with Stanford Type A Aortic Dissection.Journal of cardiothoracic surgery · 2026Article
- Validation of recipient-specific kinetic prediction scores for allograft failure after liver transplantation: a single centre retrospective analysis.BMC gastroenterology · 2026Article
- Antibiotics and Other Drugs Removal by the CytoSorbAntibiotics (Basel, Switzerland) · 2026Review
- Knowledge gaps in extracorporeal blood purification: what would be required for its successful application in septic shock?Intensive care medicine experimental · 2025Review
- The international, prospective CytOSorbJournal of intensive medicine · 2025Article
- Impact of hemoadsorption with CytoSorb® on meropenem and piperacillin exposure in critically ill patients in a post-CKRT setup: a single-center, retrospective data analysis.Intensive care medicine experimental · 2025Article
- To Hemoadsorb or Not to Hemoadsorb-Do We Have the Answer Yet? An Updated Meta-Analysis on the Use of CytoSorb in Sepsis and Septic Shock.Biomedicines · 2025Article
- Use of extracorporeal blood purification therapies in sepsis: the current paradigm, available evidence, and future perspectives.Critical care (London, England) · 2024Review
- Endothelial Protection and Improved Micro- and Macrocirculation with Hemoadsorption in Critically Ill Patients.Journal of clinical medicine · 2024Review
- The COSMOS Registry of CytoSorb Hemoadsorption Therapy in Critically Ill Patients: Protocol for an International, Prospective Registry.JMIR research protocols · 2024Observational
- Extracorporeal Elimination of Pro- and Anti-inflammatory Modulators by the Cytokine Adsorber CytoSorbInfectious diseases and therapy · 2024Article
- Systematic review with expert consensus on use of extracorporeal hemoadsorption in septic shock: An Indian perspective.World journal of critical care medicine · 2024Article
- Current clinical practice in using adjunctive extracorporeal blood purification in sepsis and septic shock: results from the ESICM "EXPLORATION" survey.Intensive care medicine experimental · 2024Article
- Current perspectives in the management of sepsis and septic shock.Frontiers in medicine · 2024Review
- Hemoadsorption in Organ Preservation and Transplantation: A Narrative Review.Life (Basel, Switzerland) · 2023Review
- Adjunctive Hemoadsorption Therapy with CytoSorb in Patients with Septic/Vasoplegic Shock: A Best Practice Consensus Statement.Journal of clinical medicine · 2023Review
- Hemoadsorption as Adjuvant Therapy in Acute Respiratory Distress Syndrome (ARDS): A Systematic Review and Meta-Analysis.Biomedicines · 2023Review
- Hemoadsorption Using CytoSorbJournal of cardiovascular development and disease · 2023Article
- The Techniques of Blood Purification in the Treatment of Sepsis and Other Hyperinflammatory Conditions.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the current paper is to summarize the results of the International CytoSorb Registry. Data were collected on patients of the intensive care unit. The primary endpoint was actual in-hospital mortality compared to the mortality predicted by APACHE II score. The main secondary endpoints were SOFA scores, inflammatory biomarkers and overall evaluation of the general condition. 1434 patients were enrolled. Indications for hemoadsorption were sepsis/septic shock (N = 936); cardiac surgery perioperatively (N = 172); cardiac surgery postoperatively (N = 67) and "other" reasons (N = 259). APACHE-II-predicted mortality was 62.0±24.8%, whereas observed hospital mortality was 50.1%. Overall SOFA scores did not change but cardiovascular and pulmonary SOFA scores decreased by 0.4 [-0.5;-0.3] and -0.2 [-0.3;-0.2] points, respectively. Serum procalcitonin and C-reactive protein levels showed significant reduction: -15.4 [-19.6;-11.17] ng/mL; -17,52 [-70;44] mg/L, respectively. In the septic cohort PCT and IL-6 also showed significant reduction: -18.2 [-23.6;-12.8] ng/mL; -2.6 [-3.0;-2.2] pg/mL, respectively. Evaluation of the overall effect: minimal improvement (22%), much improvement (22%) and very much improvement (10%), no change observed (30%) and deterioration (4%). There was no significant difference in the primary outcome of mortality, but there were improvements in cardiovascular and pulmonary SOFA scores and a reduction in PCT, CRP and IL-6 levels. Trial registration: ClinicalTrials.gov Identifier: NCT02312024 (retrospectively registered).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.